Ryan Livingston

A new meta-analysis has contrasted the association between the 2 conditions against the general population, psoriasis, rheumatoid arthritis, and ankylosing spondylitis.

The investigational therapy from Innovent Biologics, Inc. displayed significantly greater urate-lowering efficacy versus febuxostat, along with a favorable safety profile.

Allopurinol and febuxostat, recently associated with significant risk of macrovascular disorders, have no increased risk of microvascular conditions.

Using an established full and simplified definition, investigators found a substantial percentage of the MIRROR population achieved gout remission.

Recent research identifies 4 SNPs in the GCKR gene as significant genetic risk factors for gout, enhancing understanding of the disease's genetic basis.

With the exception of duloxetine, milnacipran, and pregabalin, most therapies exhibited insignificant results in reducing pain.

Patients with concurrent type 2 diabetes mellitus and psoriatic arthritis who have a BMI below 30 kg/m2 exhibit higher all-cause mortality and lower 5-year survivability than those with higher BMI measurements.

3-year interim analysis of the SERENA study confirmed the safety of secukinumab to treat psoriatic arthritis and ankylosing spondylitis.

Tumor necrosis factor-α inhibitors are suggested as the optimal treatment for both joint and skin symptoms.

Investigators call for faster diagnosis and better treatment for psoriatic arthritis to avoid unnecessary complication and suffering.

Anti-IL-17 medications meant to treat psoriasis and psoriatic arthritis may inadvertently harm gastrointestinal tract.

Dual-energy computed tomography results in faster dissolution of both the core and crown of tophi.

hsCRP may be a more accessible and reliable method of indicating inflammation, a known precursor to PsA.

Despite common practice avoiding benzbromarone, new data suggest it has a relatively low hepatotoxicity versus its more common counterpart in gout.